Related Experiment Video

Updated: May 4, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

19.0K

Targeting the LKB1 tumor suppressor

Rui-Xun Zhao, Zhi-Xiang Xu1

  • 1Division of Hematology and Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, 1824 6th Avenue South, Wallace Tumor Institute Building, Room 520D, Birmingham, AL 35294, USA. zhixiangxu@uabmc.edu.

Current Drug Targets
|January 7, 2014
PubMed

Insights

Serine-threonine kinase 11 (LKB1) is a tumor suppressor involved in cell functions and cancer. This review discusses agents targeting aberrant LKB1 signaling for personalized cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • LKB1 (serine-threonine kinase 11) is a crucial tumor suppressor gene.
  • Mutations in LKB1 are linked to Peutz-Jeghers syndrome and various cancers.
  • LKB1 regulates fundamental cellular processes including metabolism, cell cycle, polarity, and apoptosis.

Purpose of the Study:

  • To review the role of LKB1 in cancer and its physiological functions.
  • To discuss current therapeutic strategies targeting aberrant LKB1 signaling.
  • To explore potential agents and challenges in LKB1-targeted cancer therapy.

Main Methods:

  • Literature review of studies on LKB1 function and therapeutic targeting.
  • Analysis of agents with activity against LKB1 signaling pathways.
  • Discussion of challenges and future directions in LKB1-targeted therapy.

Main Results:

  • LKB1 plays a significant role in tumor suppression and cellular homeostasis.
  • Aberrant LKB1 signaling is implicated in the development and progression of diverse cancers.
  • Several therapeutic agents show potential for targeting LKB1-driven cancers.

Conclusions:

  • Targeting LKB1 inactivation represents a promising avenue for personalized cancer medicine.
  • Further research is needed to overcome challenges in developing effective LKB1-targeted therapies.
  • Understanding LKB1's multifaceted roles is key to advancing cancer treatment strategies.

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

300
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

2.6K